Knight Therapeutics Inc (GUD)

5.27
+0.05(+0.96%)
  • Volume:
    20,306
  • Bid/Ask:
    5.26/5.27
  • Day's Range:
    5.22 - 5.27
  • Type:Equity
  • Market:Canada
  • ISIN:CA4990531069
  • CUSIP:499053106

GUD Overview

Prev. Close
5.22
Day's Range
5.22-5.27
Revenue
261.22M
Open
5.22
52 wk Range
5.01-5.74
EPS
-0.07
Volume
20,306
Market Cap
607.57M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
202,959
P/E Ratio
-
Beta
0.52
1-Year Change
-4.22%
Shares Outstanding
115,289,117
Next Earnings Date
Aug 11, 2022
What is your sentiment on Knight Therapeutics Inc?
or
Vote to see community's results!

Knight Therapeutics Inc Analysis

Knight Therapeutics Inc Company Profile

Knight Therapeutics Inc Company Profile

Employees
660
Market
Canada

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Sell
SummaryBuyStrong BuyStrong BuySellStrong Sell